

CORRIGENDUM

Cawley N, Tur C, Prados F, et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.

Mult Scler . Epub ahead of print 18 May 2017. DOI: 10.1177/1352458517709954.

On page 9 of this article, the Declaration of Conflicting Interests and Funding statements were incorrect. The correct declarations are shown below.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: A.T. has received honoraria and support for travel from Eisai and EXCEMED. He has received support for travel from the International Progressive MS Alliance, as chair of their Scientific Steering Committee and the National MS Society (USA) as a member of their Research Programs Advisory Committee. He receives an honorarium from SAGE Publishing as Editor-in-Chief of Multiple Sclerosis. O.C. acts as a consultant for Novartis, Biogen, Roche, Teva, Genzyme and GE Healthcare. She receives an honorarium from AAN as Associate Editor of Neurology.

Funding

The author(s) declared receipt of the following financial support for the research, authorship and/or publication of this article:

This study was funded by the UK MS Society and supported by the National Institute for Health Research University College London Hospital's Biomedical Research Centre.

The online version of this article has been updated to reflect the correct declarations.

Subsequent versions of the article will also be corrected.

The authors apologise for this error and any confusion it may have caused.